Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Ligand Pharmaceuticals (LGND) stock in plain English

Free brief · no signupStart here
LGNDPublished Nov 12, 2026
Ligand Pharmaceuticals Inc
Healthcare · Biotechnology
Licenses drug formulation technologies and provides financing to biopharmaceutical partners. Collects milestone payments and recurring royalties on commercial product sales.
Assets:
Captisol platformProduces cyclodextrin solubility agents used in commercial injectable therapies
Pelican platformExpresses complex proteins for recombinant drug production
San Diego headquartersHouses executive management and commercial transaction teams in California
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

58
OPS ScoreOperating finances
Latest quote
-3.94%$286.94
$5.74B
128.0×
$253.85M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 12, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was LGND. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Ligand Pharmaceuticals (LGND) do?

Ligand Pharmaceuticals Inc (LGND) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Licenses drug formulation technologies and provides financing to biopharmaceutical partners. Collects milestone payments and recurring royalties on commercial product sales. It is worth $5.74B on the market and sold $253.85M over the last year.

Market cap
$5.74B
P/E ratio
128.0×
Annual sales
$253.85M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 12, 2026

Brands and businesses behind LGND

  • Captisol: Sells a modified cyclodextrin agent to drug makers to improve the solubility and stability of approved medicines.

LGND’s flags, in plain English

Each flag is a number from Ligand Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.

Wide Gross Margin

Gross margin of 81.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Profit with Caveats

Bottom-line profit of $51M in the 12 months to Sep 30, 2026, next to $24M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about LGND

How big is Ligand Pharmaceuticals?

Ligand Pharmaceuticals’ market cap is $5.74B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $253.85M: what customers paid the company over the last year, before any costs.

What is LGND’s P/E ratio?

LGND’s P/E ratio is 128.0×. Investors pay about 128.0 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with LGND?

Revenue depends directly on clinical trial outcomes and commercial sales managed by outside partner companies. That is one risk on Ligand Pharmaceuticals’ card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Ligand Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. LGND’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card